Pyxis Oncology, Inc. (PYXS)

Develops antibody-drug conjugates (ADCs) and immunotherapies for cancer treatment, focusing on novel approaches.

PYXS Stock Quote

Company Report

Pyxis Oncology, Inc., headquartered in Cambridge, Massachusetts, is a pioneering biopharmaceutical company focused on advancing therapies for the treatment of various cancers. Operating at the forefront of immune-oncology, Pyxis Oncology develops a robust pipeline of innovative product candidates aimed at addressing significant unmet medical needs in oncology.

The company's portfolio includes PYX-106, a promising fully human immunoglobulin G1 isotype siglec-15 targeting antibody under investigation for thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, Pyxis Oncology is developing PYX-102, an immune-therapeutic designed for the treatment of solid tumors, further expanding its therapeutic capabilities in oncology.

Founded in 2018, Pyxis Oncology combines cutting-edge science with strategic innovation to accelerate the development of antibody drug conjugate (ADC) product candidates. These include PYX-201 for NSCLC and breast cancer, PYX-202 targeting small cell lung cancer (SCLC) and soft tissue sarcoma, and PYX-203 for acute myeloid leukemia and myeloid dysplastic syndrome. With a commitment to advancing oncology treatments, Pyxis Oncology continues to push boundaries in cancer therapy research and development.

PYXS EPS Chart

PYXS Revenue Chart

Stock Research

MLCO CBNK GHIX BMY CTSO GPK SR

PYXS Chart

View interactive chart for PYXS

PYXS Profile

PYXS News

Analyst Ratings